Dasatinib
Precursor Lymphoblastic Lymphoma/Leukemia
Explore 20 assets in Precursor Lymphoblastic Lymphoma/Leukemia →Floatz Rating
D30/100
Confidence
Indicative
Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Modality
Small molecule
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05024357CT.gov A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL | — | Unknown | — | — | — |
NCT05026229CT.gov A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Precursor Lymphoblastic Lymphoma/Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dasatinib (this asset) | First Affiliated Hospital Xi'an Jiaotong University | N/A | D · 30 |
| Lidocaine | CAMC Health System | P4 | BB |
| Dexasone | Institute of Hematology & Blood Diseases Hospital, China | P2 | B |
| Cyclophosphamide | Institute of Hematology & Blood Diseases Hospital, China | P2 | B |
| Etoposide | Asan Medical Center | P2 | B |
| Daratumumab | Janssen Research & Development, LLC | P2 | B |
| Mercaptopurine Anhydrous | Institute of Hematology & Blood Diseases Hospital, China | P2 | B |
| Prednisone | Institute of Hematology & Blood Diseases Hospital, China | P2 | B |
| Adriamycin | Janssen Research & Development, LLC | P2 | B |
+25 more in the Precursor Lymphoblastic Lymphoma/Leukemia cohort
Other indications for Dasatinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Acute Lymphoblastic Leukemia | — | P3 | BB · 70 |
| Chronic Myeloid Leukemia | — | P2/3 | BB · 68 |
| B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2) | — | P3 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dasatinib in Precursor Lymphoblastic Lymphoma/Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dasatinib-precursor-lymphoblastic-lymphomaleukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →